Mathematical model of influenza a virus production in large-scale microcarrier culture

Biotechnology and Bioengineering

Volumn 90, Issue 1, 2005, Pages 46-58

  Möhler, Lars ^a   Flockerzi, Dietrich ^b   Sann, Heiner ^b   Reichl, Udo ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

Author keywords

Animal cell culture; Influenza virus; Mathematical model; Vaccine production; Virus dynamics

Indexed keywords

ANIMAL CELL CULTURE; ANTIBODIES; BIOASSAY; BIOLOGICAL ORGANS; CELLS; MATHEMATICAL MODELS; OPTIMIZATION;

HEMAGGLUTINATION ASSAYS (HA); INFLUENZA A VIRUS; MICROCARRIER CULTURE; MULTIPLICITY OF INFECTION (MOI); VIRUS REPLICATION;

VIRUSES;

FLUORESCENT DYE; INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DEATH; CELL LABELING; CELL STRAIN; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE OPTIMIZATION; DYNAMICS; FLUORESCENT ANTIBODY TECHNIQUE; INFECTION RATE; INFLUENZA VIRUS A; MATHEMATICAL MODEL; MICROCARRIER CULTURE; NONHUMAN; PARAMETER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TECHNIQUE; VACCINE PRODUCTION; VIRION; VIROGENESIS; VIRUS ADSORPTION; VIRUS CULTURE; VIRUS HEMAGGLUTINATION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; BIOREACTORS; CELL COUNT; CELL LINE; CELL PROLIFERATION; COMPUTER SIMULATION; DOGS; INFLUENZA A VIRUS; KIDNEY; MODELS, BIOLOGICAL; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 17444405938     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20363     Document Type: Article

References (48)

1. Arden N, Betenbaugh MJ. 2004. Life and death in mammalian cell culture: strategies for apoptosis inhibition. Trends Biotechnol 22:174-180.
2. Bancroft CT, Parslow TG. 2002. Evidence for segment-nonspecific packaging of the influenza A virus genome. J Virol 76:7133-7139.
3. Dee KU, Shuler ML. 1997. A mathematical model of the trafficking of acid-dependent enveloped viruses: applied to the binding, uptake, and nuclear accumulation of baculovirus. Biotechnol Bioeng 54: 468-490.
4. Dee KU, Hammer DA, Shuler ML. 1995. A Model of the binding, entry, uncoating, and RNA synthesis of Semliki Forest virus in baby hamster kidney (BHK-21) cells. Biotechnol Bioeng 46:485-496.
5. De Gooijer CD, Koken RHM, Van Lier FLJ, Kool M, Vlak JM, Tramper JA. 1992. Structured dynamic model for the baculovirus infection process in insect-cell reactor configurations. Biotechnol Bioeng 40: 537-548.
6. Endy D, Kong D, Yin J. 1997. Intracellular kinetics of a growing virus: a genetically structured simulation for bacteriophage T7. Biotechnol Bioeng 55:375-389.
7. Ermentrout B. 2002. Simulating, analyzing, and animating dynamical systems: a guide to XPPAUT for researchers and students. Philadelphia, PA: Society for Industrial and Applied Mathematics. 290 p.
8. Eshima N, Tabata M, Kikuchi H, Karukaya S, Taguchi T. 2001. Analysis of the infection system of human T-cell leukaemia virus type I based on a mathematical epidemic model. Stat Med 20:3891-3900.
9. Fenner F, McAuslan BR, Mims CA, Sambrook J, White DO. 1974. The biology of animal viruses. 2nd ed. San Diego, CA: Academic Press, p 177.
10. Flint JS, Racaniello VR, Krug R. 2000. Principles of virology: molecular biology, pathogenesis, and control. Washington, DC: ASM Press. 804 p.
11. Funk GA, Fischer M, Joos B, Opravil M, Gunthard HF, Ledergerber B, Bonhoeffer S. 2001. Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acq Immun Def Synd 26:397-404.
12. Funk W, Dammann V, Donnevert G. 1995. Quality assurance in analytical chemistry. Weinheim: VCH.
13. Genzel Y, Voges L, Reichl U. 2001. Development of bioprocess concepts on vaccine production: influenza virus as an example. In: Proceedings from the seventeenth ESACT meeting. Animal cell technology: from target to market. Tylosand, Sweden. p 344-346.
14. Genzel Y, Behrendt I, König S, Sann H, Reichl U. 2004. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22:2202-2008.
15. Gilchrist MA, Coombs D, Perelson AS. 2004. Optimizing within-host viral fitness: infected cell lifespan and virion production rate. J Theor Biol 229:281-288.
16. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. 1999. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 98:39-51.
17. Jang JD, Sanderson CS, Chan LCL, Barford JP, Reid S. 2000. Structured modeling of recombinant protein production in batch and fed-batch culture of baculovirus-infected insect cells. Cytotechnology 34: 71-82.
18. Kessler N, Thomas-Roche G, Gerentes L, Aymard M. 1999. Suitability of MDCK cells grown in serum-free medium for influenza virus production. Dev Biol Stand 98:13-21.
19. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. 1998. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960-968.
20. Knipe DM, Howley PM, Griffin DE. 2001. Fields' virology. 4th ed. Lippincott/Williams & Wilkins.
21. Krogstad P, Uittenbogaart CH, Dickover R, Bryson YJ, Plaeger S, Garfinkel A. 1999. Primary HIV infection of infants: the effects of somatic growth on lymphocyte and virus dynamics. Clin Immunol 92: 25-33.
22. Licari P, Bailey JE. 1992. Modeling the population dynamics of baculovirus-infected insect cells: optimizing infection strategies for enhanced recombinant protein yields. Biotechnol Bioeng 39: 432-441.
23. Lin C, Holland RE, Donofrio JC, McCoy MH, Tudor LR, Chambers TM. 2002. Caspase activation in equine influenza virus induced apoptotic cell death. Vet Microbiol 84:357-365.
24. Mahy BWJ, Kangro HO. 1996. Virology methods manual. London: Academic press. p 41-43.
25. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. 2001. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med 7:619-624.
26. Nelson PW, Perelson AS. 2002. Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 179:73-94.
27. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182:28-35.
28. Neumann G, Kawaoka Y. 1999. Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Adv Virus Res 53:265-300.
29. Nicholson KG, Webster RG, Hay AJ. 1998. Textbook of influenza. Oxford: Blackwell Science. 578 p.
30. Neumann G, Kawaoka Y. 2001. Reverse genetics of influenza virus. Virology 287:243-250.
31. Nielsen LK. 2000. Virus production from cell culture kinetics. In: Spier RE, editor. Encyclopedia of cell technology. Vol 2. New York: John Wiley & Sons. p 1217-1230.
32. Nowak MA, May RM. 2000. Virus dynamics: Mathematical principles of immunology and virology. New York: Oxford University Press. 237 p.
33. Nunes-Correia I, Ramalho-Santos J, Nir S, Pedroso de Lima MC. 1999. Interactions of influenza virus with cultured cells: detailed kinetic modeling of binding and endocytosis. Biochemistry 38:1095-1101.
34. Olsen CW, Kehren JC, Dybdahl-Sissoko NR, Hinshaw VS. 1996. Bcl-2 alters influenza virus yield, spread, and hemagglutinin glycosylation. J Virol 70:663-666.
35. Palese P, Zheng H, Engelhardt OG, Pleschka S, Garcia-Sastre A. 1996. Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA 93:11354-11358.
36. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. 2001. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19: 2716-2721.
37. Reddy B, Yin J. 1999. Quantitative intracellular kinetics of HIV type 1. AIDS Res Hum Retrov 15:273-283.
38. Reichl U. 2000. ISCOM vaccines-antigen production and downstream processing. In: Proceedings of the fourth international congress on biochemical engineering. Stuttgart: Fraunhofer IRB Verlag. p 314-318.
39. Rimmelzwaan GF, Baars M, Claas ECJ, Osterhaus ADME. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74: 57-66.
40. Robertson JS, Cook P, Attwell A-M, Williams SP. 1995. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue culture derived virus: implications for vaccine manufacture. Vaccine 13:1583-1588.
41. Roitt I, Brostoff J, Male D. 1989. Immunology. 2nd ed. London: Gower Medical. 480 p.
42. Roy AM, Parker JS, Parrish CR, Whittaker GR. 2000. Early stages of influenza virus entry into Mv-1 lung cells: involvement of dynamin. Virology 267:17-28.
43. Sidorenko I, Reichl U. 2003. A structured model of influenza virus replication in MDCK cells. Biotechnol Bioeng (in press).
44. Tränkle F, Kienle A, Mohl KD, Zeitz M, Gilles ED. 1999. Object-oriented modeling of distillation processes. Comput Chem Eng 23: 743-746.
45. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. 2001. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19: 3444-3450.
46. Voeten JTM, Brands R, Palache AM, van Scharrenberg GJM, Rimmelzwaan GF, Osterhaus ADME, Claas ECJ. 1999. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine 17:1942-1950.
47. Wodarz D, Nowak MA, Bangham CR. 1999. The dynamics of HTLV-I and the CTL response. Immunol Today 20:220-227.
48. Zhao S, Xu Z, Lu Y. 2000. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in china. Int J Epidemiol 29:744-752.